In Ventura County, the rent is high and getting higher
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
MannKind reports higher revenue, lower losses in Q3
MannKind Corp. reported a substantial rise in revenue and a shrinking net loss in the third quarter of 2021 on Nov. 9, despite news since the quarter ended that the U.S. Food and Drug Administration will not yet approve a hypertension treatment the company is developing with United Therapeutics. MannKind, a Westlake Village-based biotechnology company Read More →
Atara reports growing losses, but plenty of cash left
Atara Biotherapeutics continued seeing losses in the third quarter of fiscal year 2021, but has enough cash on hand to remain solvent as it awaits news on its tab-cel therapy treatment in early 2022. Atara, a South San Francisco-based immunotherapy based company with major operations in Westlake Village, reported net losses of $84.7 million in Read More →
PennyMac Financial reports profit while investment trust records loss in Q3
Westlake Village-based PennyMac Financial Services saw its net income drop in the third quarter compared to the year before, but officials reported “exceptional financial performance” in other areas in earnings released Nov. 4. The mortgage lender and loan servicer reported net income of $249.3 million in the third quarter, or $3.80 per share on a Read More →
Velocity Financial reports earnings growth in Q3
Westlake Village-based mortgage lender Velocity Financial reported an increase in net income and net interest margin for the third quarter, compared to the same quarter last year, in an earnings statement released Nov. 3. Velocity reported net income of $8.02 million in the third quarter, or 23 cents per diluted share, compared to $3.5 million, Read More →
Amgen reports revenue growth in Q3 but lowers full-year guidance
Sales increases across Amgen’s drug lineup drove increases in revenue and non-GAAP earnings at the Thousand Oaks biotech company during the third quarter, according to its Nov. 2 earnings release, but pandemic issues persist, and the company lowered its revenue guidance for the year. Amgen, one of the largest biotech companies in the world, reported Read More →
VCEDA’s departure marks the end of an economic development era
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
